A Phase 2 Study of Neratinib with or without Fulvestrant in HER2-Positive ER-Positive Metastatic Breast Cancer
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Conditions: breast cancer
Age: Between 18 - 100 Years
In order to be eligible to take part in this trial, patients must meet the following criteria:
- Females 18 years or older
- Inoperable locally advanced or metastatic ER+ breast cancer.
For a full list of participation criteria, please visit clinicaltrials.gov.
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required